BEIJING, Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of "microalgae-derived extracellul

MONTREAL, Sept. 12, 2025 /PRNewswire/ - A concerted effort by the World Federation of Hemophilia (WFH) and its partners has led to the World Health Organization (WHO) updating its Essential Medicines List (EML) and the Essential Medicines List for Children (EMLc) to better align the EMLs to the international clinical guidelines for the management of hemophilia and von Willebrand Disease (VWD). These revisions will have a positive impact on lives of people with bleeding disorders (PWBDs) everywhe

Bengaluru: Kenvue's interim CEO Kirk Perry met Robert F. Kennedy Jr. to try and dissuade him from listing Tylenol as a potential cause of autism in an upcoming report, the Wall Street Journal said on Friday, citing a person familiar with the matter. Perry argued at the hastily scheduled meeting this week that there was no clear link between the two, the report said. WSJ reported on September 5 that the U.S. health secretary planned to announce that the use of Tylenol, a popular over-the-counter

Acquisition to Enhance Technological Advancements and Expand Market Share in Digital Microsurgery GOLETA, Calif., Sept. 12, 2025 /PRNewswire/ -- B. Braun SE, a leading medical technology company, today announced the full acquisition of True Digital Surgery (TDS), a company based in Goleta, California, specializing in digital robotic-assisted 3D surgical microscopy. This acquisition highlights B. Braun's commitment to investing in the future of digital microsurgery and to expanding its market sha

New report urges CMS reforms and legislative efforts to encourage greater recognition of how primary care is valued. WASHINGTON, DC, UNITED STATES, September 12, 2025 / EINPresswire.com / -- A new report from the Commonwealth Foundation, authored by health policy experts David Muhlestein, Yuvraj Pathak, and Samia Imtiaz, calls for reform to how primary care is valued and paid for in the U.S. The report discusses how physician payments are set in Medicare under the Resource-Based Relative Value S

September 12, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company’s website at www.biodexapharma.com. OPERATIO

HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the publication of an opinion editorial authored by company leadership that presents the scientific case for fibroblast cells' therapeutic advantages compared to ste

JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”), today announced that it has received a written notice (the “Notice”), dated September 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement set forth under Na

Adding Mastisol Liquid Adhesive improves dressing durability, reduces changes, saves costs — with promising signs for infection prevention FERNDALE, Mich., Sept. 12, 2025 /PRNewswire/ -- A multicenter randomized controlled trial published in Critical Care Medicine has found that adding Mastisol® Liquid Adhesive — a gum mastic adhesive marketed by Eloquest Healthcare — to standard jugular central line dressings cut dressing failure rates nearly in half, extended wear time more than twofold, and s

BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it received a staff determination letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), dated September 11, 2025, notifying that the Company is not